Exporting human blood plasma accounts for nearly three percent of all total export goods leaving the United States economy, effectively making it one of the most lucrative industries in the nation.

How a paid donation becomes an export

The trade starts with a person, but what companies sell abroad is not usually a bag of plasma in its original form. Plasma is the liquid part of blood, carrying proteins that help with tasks such as blood clotting and immune defense. At a collection center, a process called plasmapheresis separates plasma from blood cells and returns the cells to the donor. The collected plasma is then tested, frozen, and sent for further processing.

That separation matters economically: plasma can be collected while preserving the cells, and donors can be paid for their time. For people facing a cash shortfall, payment makes donation an immediate source of income. For manufacturers, a large, steady supply is the raw material needed to make therapies that patients may depend on regularly.

The valuable step happens in processing

Manufacturers combine plasma from many donations and use a process called fractionation to separate its proteins. Those proteins become medicines, including treatments for people with immune deficiencies or certain bleeding disorders. The result is a chain that turns many individual donations into standardized products that can be stored, prescribed, and shipped internationally.

This is why export figures can reflect much more than the value of the fluid at collection. The commercial value grows as plasma is tested, pooled, separated, and converted into finished therapies. Processing also requires specialized facilities and quality controls: a donated unit is not a ready-to-use medicine, and not every collection becomes a product that can be sold.

A supply chain with human stakes

The system links donors’ need for money to demand for medicines across borders. Collection networks provide manufacturers with a dependable supply; manufacturers and distributors reach markets that may not collect enough plasma locally. The trade can therefore support both donor income and access to treatment, while concentrating substantial value in the companies that process and sell the products.

The striking detail is that an export industry can begin with a transaction measured in minutes at a collection center—but its most valuable goods emerge only after many donations pass through a demanding industrial process.